Journal of
Medicinal Plants Research

  • Abbreviation: J. Med. Plants Res.
  • Language: English
  • ISSN: 1996-0875
  • DOI: 10.5897/JMPR
  • Start Year: 2007
  • Published Articles: 3834

Full Length Research Paper

A novel anti-triple negative breast cancer compound isolated from medicinal herb Myrothamnus flabellifolius

Jaspal Brar
  • Jaspal Brar
  • Department of Biological Sciences, University of the Sciences in Philadelphia, PA 19104, USA.
  • Search for this author on:
  • Google Scholar
Norman Fultang
  • Norman Fultang
  • Department of Biological Sciences, University of the Sciences in Philadelphia, PA 19104, USA.
  • Search for this author on:
  • Google Scholar
Kayla Askey
  • Kayla Askey
  • Department of Pharmacy, University of the Sciences in Philadelphia, PA 19104, USA.
  • Search for this author on:
  • Google Scholar
Maria Cristina Tettamanzi
  • Maria Cristina Tettamanzi
  • Department of Chemistry, Temple University, Philadelphia, PA 19122, USA.
  • Search for this author on:
  • Google Scholar
Bela Peethambaran
  • Bela Peethambaran
  • Department of Biological Sciences, University of the Sciences in Philadelphia, PA 19104, USA.
  • Search for this author on:
  • Google Scholar


  •  Received: 12 October 2017
  •  Accepted: 12 December 2017
  •  Published: 03 January 2018

Abstract

Triple negative breast cancer (TNBC) is a disease that impacts millions of people around the world. There is an urgent need to find new therapies, specific to triple negative cancer cells with minimal effect on normal cells. This study explores the use of Myrothamnus flabellifolius as an anti-TNBC. Using High Performance Liquid Chromatography, the extract was fractionated and each fraction was tested against TNBC cells BT-549 and MDA-MB-231, and a non-malignant breast cell line MCF-10A. The results showed that fraction 7 inhibited the growth of TNBC cells starting at a dry weight concentration of 31.125 μg/mL while there was no significant cell death of the MCF-10A cell line. Using analytical techniques such as Mass Spectrometry (MS-MS) and Nuclear Magnetic Resonance (NMR), the major compound in fraction 7 was determined to be a derivative of galloyl glucose hexahydroxydiphenic acid. The results suggest that this novel compound is the primary anti-TNBC compound in M. flabellifolius and might be a potential candidate for targeted TNBC therapy.
 
Key words: Triple negative breast cancer, Myrothamnus flabellifolius, natural products, galloyl glucose hexahydroxydiphenic acid derivative.

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 12 No. 1
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES